Cell-specific establishment of poliovirus resistance to an inhibitor targeting a cellular protein

Ekaterina G Viktorova1, Jules Nchoutmboube1, Lauren A Ford-Siltz1

  • 1Department of Veterinary Medicine, University of Maryland, College Park, Maryland, USA.

Journal of Virology
|February 6, 2015
PubMed
Abstract

Insights

Targeting cellular factors for antiviral drugs, like poliovirus resistance to brefeldin A (BFA), shows resistance emergence is cell type dependent. This host-targeting strategy may overcome viral adaptability.

Area of Science:

  • Virology
  • Cell Biology
  • Drug Discovery

Background:

  • Developing antiviral drugs is crucial due to limited vaccines and viral adaptability.
  • Targeting host cellular factors offers an alternative to targeting viral proteins to combat resistance.
  • Poliovirus resistance to brefeldin A (BFA), an inhibitor of cellular protein GBF1, was investigated.

Purpose of the Study:

  • To analyze factors influencing the development of poliovirus resistance to brefeldin A (BFA).
  • To understand the cell type-dependent nature of antiviral resistance.
  • To explore the potential of host-targeting antivirals against (+)RNA viruses.

Main Methods:

  • Selection of poliovirus mutants resistant to BFA in different cell lines (HeLa and Vero).
  • Assessment of viral replication efficiency and fitness in the presence and absence of BFA.
  • Analysis of GBF1 recruitment to viral replication complexes.

Main Results:

  • Poliovirus resistance to BFA was easily selected in HeLa cells but not in Vero cells.
  • Viral replication was more resilient to BFA than the cellular secretory pathway.
  • GBF1 recruitment to replication complexes limited BFA resistance phenotype establishment.
  • BFA resistance in poliovirus mutants was cell type-dependent and resulted in reduced fitness.

Conclusions:

  • The emergence of antiviral resistance is influenced by host cell type.
  • GBF1's role in poliovirus replication is independent of its Arf activating function.
  • Host-targeting antiviral strategies can be rationally designed to overcome viral adaptability.